Seattle Children’s announced they are now enrolling participants in the first CAR T cell clinical trial for children with systemic lupus erythematosus (SLE). This is the first clinical trial in the U.S. examining CAR T cell therapy in a pediatric population.
The phase 1 trial, Reversing Autoimmunity through Cell Therapy, or REACT-01, plans to enroll 12 participants ages 2 to 30 living with lupus that is resistant to current treatment regimens, but the first three participants to enroll must be age 17 or older. CAR-T cells are genetically altered cells that are designed to reset the immune system. CAR-T cell therapy targets B cells, which are immune system cells involved in the production of autoantibodies and lupus disease activity.
Continue to follow the Lupus Foundation of America for updates on the REACT-01 study, as well as other lupus drug development news. Learn more about participating in clinical trials.
This post was originally published on this site